Drugs

, Volume 57, Issue 5, pp 653–663

Selective Estrogen Receptor Modulators

A Look Ahead
Leading Article

Abstract

Selective estrogen receptor modulators (SERMs) are structurally diverse compounds that bind to estrogen receptors (ER) and elicit agonist or antagonist responses depending on the target tissue and hormonal milieu. They are being evaluated primarily for conditions associated with aging, including hormone-responsive cancer, osteoporosis and cardiovascular disease. Several SERMs are marketed or are in clinical development, including triphenylethylenes (tamoxifen and its derivatives: toremifene, droloxifene and idoxifene), chromans (levormeloxifene), benzothiophenes (raloxifene, LY353381) and naphthalenes (CP336,156). Tamoxifen and toremifene, both used to treat advanced breast cancer, also have beneficial effects on bone mineral density and serum lipids in postmenopausal women. Tamoxifen was recently shown to decrease the risk of invasive breast cancer in women at high risk. Unfortunately, both drugs also have stimulatory effects on the endometrium. Raloxifene, used for prevention of postmenopausal osteoporosis and fragility fractures, also has favourable effects on bone mineral density, serum lipids and the incidence of invasive breast cancer in postmenopausal women but does not stimulate the endometrium. Like replacement estrogens, SERMs increase the risk of venous thromboembolism. SERMs offer postmenopausal women many of the advantages of estrogen replacement while mitigating some of the disadvantages, particularly the concern over breast cancer. Newer SERMs, exemplified by raloxifene, also eliminate the concerns over endometrial stimulation that were not addressed by first generation SERMs. The clinical success of SERMs has set the stage for a variety of drug therapies based on selective modulation of nuclear receptor activity.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ray S, Dwivedy I. Development of estrogen antagonists as pharmaceutical agents. Adv Drug Res 1997; 29: 171–270CrossRefGoogle Scholar
  2. 2.
    Stevenson J, Gaspard U, Avouac B, et al. Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Climacteric 1998; 1: 12–7PubMedCrossRefGoogle Scholar
  3. 3.
    Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753–8PubMedCrossRefGoogle Scholar
  4. 4.
    Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity of estrogen receptor modulators. Proc Natl Acad Sci U S A 1997; 94: 14105–10PubMedCrossRefGoogle Scholar
  5. 5.
    Katzenellenbogen JA, O’Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996; 10: 119–31PubMedCrossRefGoogle Scholar
  6. 6.
    McDonnell DP, Norris JD. Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone. Osteoporos Int 1997; 7 (1 Suppl.): 29–34CrossRefGoogle Scholar
  7. 7.
    Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. In: Pincus G, editor. Recent progress in hormone research: The Proceedings of the 1961 Laurentian Hormone Conference. New York: Academic Press, 1962: (18) 387–414Google Scholar
  8. 8.
    Gorski J, Toft D, Shyamala G, et al. Hormone receptors: studies on the interaction of estrogen with the uterus. In: Astwood EB, editor. Recent progress in hormone research: The Proceedings of the 1961 Laurentian Hormone Conference. New York: Academic Press, 1968: (24) 45–80Google Scholar
  9. 9.
    Anstead GM, Carlson KE, Katzenellenbogen JA. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997; 62: 268–303PubMedCrossRefGoogle Scholar
  10. 10.
    Giguere V, Tremblay A, Tremblay GB. Estrogen receptor β: re-evaluation of estrogen and antiestrogen signalling. Steroids 1998; 63: 335–9PubMedCrossRefGoogle Scholar
  11. 11.
    Murphy LC, Leygue E, Dotzlaw H, et al. Oestrogen receptor variants and mutations in human breast cancer. Ann Med 1997; 29: 221–34PubMedCrossRefGoogle Scholar
  12. 12.
    Tzukerman M, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994; 8(1): 21–30PubMedCrossRefGoogle Scholar
  13. 13.
    Danielian PS, White R, Lees JA, et al. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors [published erratum appears in EMBO J 1992; 11: 2366]. EMBO J 1992; 11: 1025–33PubMedGoogle Scholar
  14. 14.
    Nrris JD, Fan D, Kerner SA, et al. Identification of a third autonomous activation domain within the human estrogen receptor. Mol Endocrinol 1997; 11: 747–54CrossRefGoogle Scholar
  15. 15.
    Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990; 9: 2811–8PubMedGoogle Scholar
  16. 16.
    McDonnell DP, Clemm DL, Hermann T, et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995; 9: 659–69PubMedCrossRefGoogle Scholar
  17. 17.
    Feng W, Ribeiro RCJ, Wagner RL, et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998; 280: 1747–9PubMedCrossRefGoogle Scholar
  18. 18.
    Levenson AS, Jordan VC. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 1998; 58(9): 1872–5PubMedGoogle Scholar
  19. 19.
    Yang NN, Venugopalan M, Hardikar S, et al. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene [published erratum appears in Science 1997; 275: 1249]. Science 1996; 273: 1222–5PubMedCrossRefGoogle Scholar
  20. 20.
    Elgort MG, Zou A, Marschke KB, et al. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-α-1 promoter via a novel sequence. Mol Endocrinol 1996; 10: 477–87PubMedCrossRefGoogle Scholar
  21. 21.
    Webb P, Lopez GN, Uht RM, et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995; 9: 443–56PubMedCrossRefGoogle Scholar
  22. 22.
    Paech K, Webb P, Kuiper GGJM, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science 1997; 277: 1508–10PubMedCrossRefGoogle Scholar
  23. 23.
    Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258–68PubMedCrossRefGoogle Scholar
  24. 24.
    White R, Parker MG. Molecular mechanisms of steroid hormone action. Endocr Rel Cancer 1998; 5: 1–14CrossRefGoogle Scholar
  25. 25.
    Robyr D, Wolffe AP. Hormone action and chromatin remodelling. Cell Mol Life Sci 1998; 54: 113–24PubMedCrossRefGoogle Scholar
  26. 26.
    Bedford GR, Richardson DN. Preparation and identification of cis and trans isomers of a substituted triarylethylene. Nature 1966; 212: 733–4CrossRefGoogle Scholar
  27. 27.
    Harper MJ, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 1966; 212: 87PubMedCrossRefGoogle Scholar
  28. 28.
    Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 1971; 25: 270–5PubMedCrossRefGoogle Scholar
  29. 29.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–67CrossRefGoogle Scholar
  30. 30.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42PubMedCrossRefGoogle Scholar
  31. 31.
    Turken S, Siris E, Seldin D, et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989; 81: 1086–8PubMedCrossRefGoogle Scholar
  32. 32.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6PubMedCrossRefGoogle Scholar
  33. 33.
    McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995; 311: 977–80PubMedCrossRefGoogle Scholar
  34. 34.
    Grey AB, Stapleton JP, Evans MC, et al. The effect of the anti-estrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995; 99: 636–41PubMedCrossRefGoogle Scholar
  35. 35.
    Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84PubMedGoogle Scholar
  36. 36.
    Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996; 7: 671–5PubMedCrossRefGoogle Scholar
  37. 37.
    Gotfredsen A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984; 53: 853–7PubMedCrossRefGoogle Scholar
  38. 38.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998; 90(18): 1371–88PubMedCrossRefGoogle Scholar
  39. 39.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93–7PubMedGoogle Scholar
  40. 40.
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101PubMedGoogle Scholar
  41. 41.
    Ray A. Side effects of tamoxifen are distressing and common [letter]. BMJ 1996; 313: 1484PubMedCrossRefGoogle Scholar
  42. 42.
    Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151: 1842–7PubMedCrossRefGoogle Scholar
  43. 43.
    Gershanovich M, Hayes DF, Ellmen J, et al. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology 1997; 11: 29–36PubMedGoogle Scholar
  44. 44.
    Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14: 429–33PubMedGoogle Scholar
  45. 45.
    Marttunen MB, Hietanen P, Tiitinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998; 83: 1158–62PubMedCrossRefGoogle Scholar
  46. 46.
    Rauschning W, Pritchard KI. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 1994: 31: 83–94PubMedCrossRefGoogle Scholar
  47. 47.
    Coombes RC, Haynes BP, Dowsett M, et al. Idoxifene: report of a phase 1 study in patients with metastatic breast cancer. Cancer Res 1995; 55: 1070–4PubMedGoogle Scholar
  48. 48.
    Weiss S, Mulder H, Chesnut C, et al. Idoxifene reduces bone turnover in osteopenic postmenopausal women [abstract]. 80th Annual Meeting of the Endocrine Society. The Endocrine Society Program & Abstracts: 1998 June 24–27; New Orleans (LA), 403Google Scholar
  49. 49.
    Bolognese M, Moffett A, Jensen C, et al. Idoxifene is well tolerated in osteopenic postmenopausal women. [abstract no. 98.072]. North American Menopause Society 9th Annual Meeting program: 1998 Sep 16–19; Toronto (ON), 80Google Scholar
  50. 50.
    SmithKline Beecham. SmithKline Beecham emphasises research and development strengths after failed merger talks [press release]. Scrip 1998 April 22Google Scholar
  51. 51.
    Kamboj VP, Ray S, Dhawan B. Centcroman. Drugs Today 1992; 28: 227–32Google Scholar
  52. 52.
    Salman M, Ray S, Anand N, et al. Studies in antifertility agents. Stereoselective binding of d- and 1-centchromans to estrogen receptors and their antifertility activity. J Med Chem 1986; 29: 1801–3PubMedCrossRefGoogle Scholar
  53. 53.
    Skrumsager BK, Kiehr B, Bjarnason K. Levormeloxifene: escalating single oral doses in healthy postmenopausal women [abstract]. J Bone Miner Res 1997; 12: S346Google Scholar
  54. 54.
    Skrumsager BK, Kiehr B, Bjarnason K. Levormeloxifene: safety and pharmacokinetics after multiple dosing of fifty-six postmenopausal women [abstract]. J Bone Miner Res 1997; 12: S346Google Scholar
  55. 55.
    Bjarnason K, Skrumsager BK, Kiehr B. Levormeloxifene, a new partial estrogen receptor agonist demonstrates anti-resorptive and antiatherogenic properties in postmenopausal women [abstract]. J Bone Miner Res 1997; 12: S346Google Scholar
  56. 56.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9PubMedCrossRefGoogle Scholar
  57. 57.
    Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987; 258: 1183–6PubMedCrossRefGoogle Scholar
  58. 58.
    Novo Nordisk, Bagsvaerd, Denmark. Novo Nordisk levormeloxifene phase 2 clinical trial: Novo Nordisk presents phase 2 data on levormeloxifene to clinical investigators [press release]. PRNewswire 1998 June 19Google Scholar
  59. 59.
    Glasebrook AL, Phillips DL, Sluka JP. Multiple binding-sites for the antiestrogen raloxifene (LY156758) [abstract no. 607]. J Bone Miner Res 1993; 8: S268Google Scholar
  60. 60.
    Gize EA, Venugopalan M, Glasebrook AL, et al. Characterization of raloxifene binding and transactivation properties of the estrogen receptor-beta (ER beta) [abstract]. J Bone Miner Res 1997; 12: S460Google Scholar
  61. 61.
    Heaney RP, Draper MW. Raloxifene mimics estrogen in human bone remodelling kinetics. J Bone Miner Res 1996; 11 (1 Suppl.): S446Google Scholar
  62. 62.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7PubMedCrossRefGoogle Scholar
  63. 63.
    Ettinger B, Black D, Cummings S, MORE Study Group et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses [abstract no. OR23]. Osteoporos Int 1998; 8 (3 Suppl.): 11Google Scholar
  64. 64.
    Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992; 17(5): 485–95PubMedCrossRefGoogle Scholar
  65. 65.
    Polo-Kantola P, Portin R, Polo O, et al. The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women. Obstet Gynecol 1998; 91(3): 459–66PubMedCrossRefGoogle Scholar
  66. 66.
    Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women. JAMA 1998; 279: 688–95PubMedCrossRefGoogle Scholar
  67. 67.
    Bryant HU, Bales KR, Paul SM, et al. Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat brain [abstract]. Soc Neurosci Abstr 1997; 23: 2377Google Scholar
  68. 68.
    Wu X, Glinn M, Su Y, et al. Raloxifene increases hippocampal choline acetyltransferase activity in ovariectomized rats [abstract]. Soc Neurosci Abstr 1998; 24(1): 732Google Scholar
  69. 69.
    Nilsen J, Mor G, Naftolin F. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 1998; 5(4): 211–6PubMedCrossRefGoogle Scholar
  70. 70.
    Nickelsen T, Lufkin EG, Riggs BL, et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999; 24: 115–28PubMedCrossRefGoogle Scholar
  71. 71.
    Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–51PubMedCrossRefGoogle Scholar
  72. 72.
    Hulley S, Grady D, Bush T, Heart and Estrogen/progestin Replacement Study (HERS) Research Group, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13PubMedCrossRefGoogle Scholar
  73. 73.
    Bjarnason NH, Haarbo J, Byrjalsen I, et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997; 96(6): 1964–9PubMedCrossRefGoogle Scholar
  74. 74.
    Kauffman RF, Bean JS, Bensch WR. Effects of estrogen and raloxifene, a selective estrogen receptor modulator, in animal models of vascular injury. In: Rubanyi GM, Kauffman R, editors. Estrogen and the vessel wall. Amsterdam: Harwood Academic Publishers, 1998Google Scholar
  75. 75.
    Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83: 721–6PubMedCrossRefGoogle Scholar
  76. 76.
    Bryant HU, Kauffman RF, Iversen P, et al. Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys [letter]. J Clin Endocrinol Metab 1998; 83(8): 3001–2PubMedCrossRefGoogle Scholar
  77. 77.
    Clarkson TB, Anthony MS. Lack of effect of raloxifene on coronary atherosclerosis of postmenopausal monkeys: authors’ response [letter]. J Clin Endocrinol Metab 1998; 83(8): 3002–4CrossRefGoogle Scholar
  78. 78.
    Jordan VC, Glusman J, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in ≈12,000 postmenopausal women [abstract]. Program/Proceedings of the American Society of Clinical Oncology, 34th Annual Meeting 1998; Los Angeles (CA), 466Google Scholar
  79. 79.
    Castellsague J, Perez-Gutthann S, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism: a review. Drug Saf 1998; 18: 117–23PubMedCrossRefGoogle Scholar
  80. 80.
    Bryant HU, Glasebrook AL, Knadler MP, et al. A highly potent orally active selective estrogen receptor modulator [abstract]. 79th Annual Meeting of the Endocrine Society. The Endocrine Society Program & Abstracts: 1997 June 11–14; Minneapolis (MN), 548Google Scholar
  81. 81.
    Sato M, Turner CH, Wang T, et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998; 287: 1–7PubMedGoogle Scholar
  82. 82.
    Cole HW, Adrian MD, Shetler PK, et al. Comparative pharmacology of high potency selective estrogen receptor modulators (SERMs) [abstract]. J Bone Miner Res 1997; 12: S349CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Indiana University School of MedicineIndianapolisUSA
  2. 2.Eli Lilly and CompanyLilly Corporate Center DC2244IndianapolisUSA

Personalised recommendations